Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HTMC0370
- Development stage
- Phase 1
- Lead developer
- Shanghai Yidian Pharmaceutical Technology Development
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HTMC0370 is an orally bioavailable, potent, and selective small molecule inhibitor of the KRAS G12D mutant protein. Developed by Shanghai Yidian Pharmaceutical Technology Development Co., Ltd., it is designed to target advanced solid tumors harboring the KRAS G12D mutation, which is prevalent in pancreatic, colorectal, and non-small cell lung cancers. By binding to the KRAS G12D protein, HTMC0370 prevents the activation of downstream signaling pathways, such as the MAPK/ERK pathway, that drive tumor cell proliferation and survival. It is currently being evaluated in Phase 1 clinical trials in China to assess its safety, tolerability, and preliminary efficacy in patients with advanced solid tumors.
Beyond the preview
Go deeper on HTMC0370.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HTMC0370.